Incannex receives A$6.0M R&D tax incentive refund, expects A$5.1M more in 2026

Incannex Healthcare received A$6.0 million in non-dilutive funding from Australia's R&D Tax Incentive Program, with an additional A$5.1 million expected later in 2026, totaling over A$11.1 million. The non-dilutive capital strengthens the company's balance sheet and provides flexibility to advance clinical programs including IHL-42X and PSX-001 while supporting share repurchases.